In newly diagnosed CML patients, tyrosine kinase inhibitors (TKIs) targeting BCR-ABL1 are remarkably effective at eliminating most BCR-ABL1-positive cells, especially in the chronic phase (CP-CML) [2, 3]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.